Gossamer Bio shares plummeted 82% after its drug seralutinib failed to meet the primary endpoint in a Phase 3 trial for pulmonary arterial hypertension. Although the drug showed clinical improvement in walking distance, the results fell short of the predetermined statistical significance threshold required for success.